… U.S. FDA (Food and Drug Administration) for … strong presence of major pharmaceutical companies, the well … development activities, and significant government funding for cancer treatments … Leukemia o Lymphoma o Multiple Myeloma • Breast Cancer • Urothelial …

… intensive treatment approach for younger or fitter multiple myeloma patients. Results from this trial … surface of multiple myeloma cells. By binding to CD38, the drug triggers anti … and the US Food and Drug Administration (FDA). The next step for …

… and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings … in relapsed/refractory multiple myeloma, odronextamab in late- … following initial treatments at low doses. This trial is … invaluable for our drug discovery and development efforts, we …

The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma …

The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma …

… CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol. 2024;25(8 … diagnosed multiple myeloma – 4-year-follow-up from the GMMG-CONCEPT trial. Presented … treatment approved by the US FDA for patients with relapsed or refractory multiple myeloma …

… patients with relapsed/refractory multiple myeloma. In the retrospective real-world … relapsed/refractory multiple myeloma outside of a clinical trial treated with cilta … real-world setting receive treatment vs in trial settings where everything is …

… drugs, are known as “living drugs.” These personalized treatments … leukemia, lymphoma, and multiple myeloma, India is witnessing a … FDA-approved CAR-T therapies, with the Phase 2 trial … developed by Immuneel Therapeutics, offers a breakthrough treatment …

… of the Multiple Myeloma Research Foundation (MMRF), discussed challenges in multiple myeloma clinical trials … also highlighted the Horizon clinical trial and how MMRF is working … optimal dosing strategy for a drug called teclistamab to maximize efficacy …

… regimen to treat adults with newly diagnosed multiple myeloma (NDMM) … the IMROZ Phase III trial, which showed that … underway across the MM treatment spectrum, covering six potential … their partnership to jointly develop pneumococcal conjugate vaccines (PCVs …